News for 4D Molecular Therapeutics, Inc. (FDMT)

Published at

Apr 11, 2025 11:18 PM

by gurufocus.com

positive

positive

4DMT Announces New Employment Inducement Grants | FDMT Stock News

4D Molecular Therapeutics (FDMT) issued 16,500 Restricted Stock Units (RSUs) to three new non-executive employees. The RSUs were granted under the 2025

FDMT

Read more →
Published at

Apr 11, 2025 10:19 PM

by manilatimes.net

positive

positive

4DMT Announces New Employment Inducement Grants

**media[592898]**

FDMT

Read more →
Published at

Mar 10, 2025 1:14 PM

by manilatimes.net

positive

positive

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

**media[561843]**

FDMT

Read more →
Published at

Feb 28, 2025 11:00 PM

by gurufocus.com

neutral

neutral

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical a

FDMT

Read more →
Published at

Feb 28, 2025 10:14 PM

by manilatimes.net

positive

positive

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

**media[553855]**

FDMT

Read more →
Published at

Feb 18, 2025 8:33 PM

by seekingalpha.com

positive

positive

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate FDMT stock a Buy.

FDMT

Read more →
Published at

Feb 15, 2025 5:17 PM

by gurufocus.com

positive

positive

RA CAPITAL MANAGEMENT, L.P. Reduces Stake in 4D Molecular Therapeutics Inc

On December 31, 2024, RA CAPITAL MANAGEMENT, L.P. (Trades, Portfolio) executed a significant transaction involving 4D Molecular Therapeutics Inc (FDMT). The fir

RYTM.MX RYTM PCVX JANX FDMT

Read more →
Published at

Feb 15, 2025 7:57 AM

by gurufocus.com

positive

positive

BIOTECHNOLOGY VALUE FUND L P Reduces Stake in 4D Molecular Therapeutics Inc

On December 31, 2024, BIOTECHNOLOGY VALUE FUND L P (Trades, Portfolio) executed a notable transaction involving 4D Molecular Therapeutics Inc (FDMT). The firm r

FDMT

Read more →
Published at

Feb 14, 2025 10:14 PM

by gurufocus.com

positive

positive

JANUS HENDERSON GROUP PLC Reduces Stake in 4D Molecular Therapeutics Inc

On December 31, 2024, JANUS HENDERSON GROUP PLC (Trades, Portfolio) executed a significant transaction involving the reduction of its holdings in 4D Molecular T

NVDAD.BA NVDA.MI MSFT.MI JHG.AX JHG FDMT APC.DE AMZNCL.SN AMZN AAPLD.BA AAPLCL.SN AAPL.SN AAPL.BA AAPL 0RPW.L

Read more →
Published at

Feb 14, 2025 5:20 PM

by gurufocus.com

positive

positive

Deep Track Capital, LP Reduces Stake in 4D Molecular Therapeutics Inc

On December 31, 2024, Deep Track Capital, LP (Trades, Portfolio) executed a significant transaction involving 4D Molecular Therapeutics Inc (FDMT), reducing its

ITCI IMVT GH.MX GH FDMT APLS

Read more →
Published at

Jan 10, 2025 5:18 PM

by seekingalpha.com

positive

positive

4D Molecular, FDA agree on phase 3 design for DME candidate

4D Molecular Therapeutics reaches agreement with FDA for phase 3 trial design of DME candidate 4D-150, showing promising interim data results. Read more here.

FDMT

Read more →
Published at

Jan 10, 2025 2:16 PM

by manilatimes.net

positive

positive

4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway

**media[511665]**

FDMT

Read more →
Published at

Dec 7, 2024 1:08 AM

by gurufocus.com

positive

positive

BlackRock, Inc. Expands Stake in 4D Molecular Therapeutics Inc

On November 30, 2024, BlackRock, Inc. (Trades, Portfolio) made a significant move in the biotechnology sector by acquiring an additional 96,230 shares of 4D Mol

NVDAD.BA NVDAC.BA NVDA.MI NVDA MSFTD.BA MSFTCL.SN MSFTC.BA MSFTB.BA MSFT.MI MSFT FDMT CASH BLQA.DE BLK.MX BLK APC.DE AMZNCL.SN AMZN.SN AMZN.MX AMZN AMZ.DE AAPLD.BA AAPLCL.SN AAPLC.BA AAPL.SN AAPL.NE AAPL.MX AAPL.BA AAPL 0QZZ.L

Read more →
Published at

Nov 26, 2024 12:51 PM

by insidermonkey.com

positive

positive

4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now

We recently compiled a list of the 10 Oversold Healthcare Stocks To Invest In. In this article, we are going to take a look at where 4D Molecular Therapeutics, Inc.

FDMT

Read more →
Published at

Nov 25, 2024 11:26 PM

by insidermonkey.com

positive

positive

10 Oversold Healthcare Stocks To Invest In

Investing in healthcare stocks during lean economic times is generally regarded as defensive.

OGN.MX OGN-WI FDMT CRBP 0SZI.L

Read more →
Published at

Nov 21, 2024 7:58 PM

by seekingalpha.com

positive

positive

4D Molecular initiated by Morgan Stanley at underweight (NASDAQ:FDMT)

Morgan Stanley initiated coverage of 4D Molecular Therapeutics (FDMT) with an underweight rating due to concerns about the potential competitiveness of its gene therapy candidate.

MSCL.SN FDMT

Read more →
Published at

Nov 14, 2024 2:20 PM

by manilatimes.net

positive

positive

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

**media[466210]**

FDMT

Read more →
Published at

Nov 13, 2024 11:20 PM

by zacks.com

negative

negative

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -17.91% and 99.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

FDMT

Read more →
Published at

Oct 4, 2024 6:35 PM

by seekingalpha.com

neutral

neutral

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure, I'm Unsure (FDMT)

4D stock is a contrarian trade opportunity based on the market assumption that the promising Wet Amd eye disease gene therapy will not make it to market, despite evidence to the contrary.

FDMT

Read more →
Published at

Sep 25, 2024 3:35 PM

by zacks.com

negative

negative

4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

4D Molecular Therapeutics (FDMT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

FDMT

Read more →